Skip to main content
. 2021 Mar 30;9:656741. doi: 10.3389/fcell.2021.656741

FIGURE 4.

FIGURE 4

Disease-free survival (DFS) and overall survival (OS) for the prognostic nutritional index (PNI) of patients with breast cancer in different molecular subtypes in the neoadjuvant chemotherapy (NACT) group. (A,B) Kaplan-Meier analysis of DFS (A) and OS (B) for the PNI of patients with luminal A breast cancer in NACT group. (C,D) Kaplan-Meier analysis of DFS (C) and OS (D) for the PNI of patients with luminal B HER2-positive breast cancer in NACT group. (E,F) Kaplan-Meier analysis of DFS (E) and OS (F) for the PNI of patients with luminal B HER2-negative breast cancer in NACT group. (G,H) Kaplan-Meier analysis of DFS (G) and OS (H) for the PNI of patients with HER2-enriched breast cancer in NACT group. (I,J) Kaplan-Meier analysis of DFS (I) and OS (J) for the PNI of patients with triple-negative breast cancer in NACT group.